Anti-MUC18 monoclonal antibody

Drug Profile

Anti-MUC18 monoclonal antibody

Alternative Names: ABX-MA1; Monoclonal antibody ABX-MA1

Latest Information Update: 12 May 2005

Price : $50

At a glance

  • Originator Abgenix
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 12 May 2005 Discontinued - Phase-I for Malignant melanoma in USA (unspecified route)
  • 27 Jan 2004 A preclinical study has been added to the Cancer pharmacodynamics section
  • 31 Dec 2002 Enrolment in the phase I metatstatic melanoma trial is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top